Are you Dr. Yee?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
9735 Wilshire Blvd
Suite 245
Beverly Hills, CA 90212Phone+1 310-276-5298Fax+1 310-276-5299
Summary
- Dr. Andrew Yee, MD is a pulmonologist in Beverly Hills, California. He is currently licensed to practice medicine in California, New Hampshire, and Massachusetts.
Education & Training
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1980 - 1983
Universidad Autonoma de GuadalajaraClass of 1978
Certifications & Licensure
CA State Medical License 1981 - 2026
MA State Medical License 2002 - 2018
NH State Medical License 2009 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma Start of enrollment: 2016 Jun 21
- Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma Start of enrollment: 2020 Feb 14
Publications & Presentations
PubMed
- 11 citationsLifestyle considerations in multiple myelomaYael N Shapiro, Jeffrey Peppercorn, Andrew Yee, Andrew R. Branagan, Noopur Raje
Blood Cancer Journal. 2021-10-26 - 23 citationsDynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myelomaJulia Frede, Praveen Anand, Noori Sotudeh, Ricardo A. Pinto, Monica S. Nair
Nature Cell Biology. 2021-10-21 - 3 citationsObservations of the near-wall accumulation of suspended particles due to shear and electroosmotic flow in opposite directions.Andrew Yee, Minami Yoda
Electrophoresis. 2021-10-08
Press Mentions
Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022- Karyopharm’s Selinexor Combination for Multiple Myeloma Unlikely to See Second-Line Use Despite Likely FDA ApprovalDecember 18th, 2020
Amyloidosis Treatments Miss the Heart of the ProblemDecember 7th, 2016- Join now to see all
